New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.
Comments closedTag: antiviral drugs
Topic: long COVIDView all posts for the topic: long COVID
Video | Akiko Iwasaki on what causes long COVID, brain fog, the Yale Paxlovid study and long COVID treatments
Published April 26, 2024
Still COVIDing Canada Posts
Published by: American Medical Association (AMA)
Published on:
What causes long COVID? Is long COVID dangerous? Who is most likely to get long COVID? Any pediatric long COVID news? What can be done for long term COVID?
Our guest is Akiko Iwasaki, PhD, Sterling Professor of Immunobiology at Yale University. AMA Chief Experience Officer Todd Unger hosts.
Comments closedTopic: antiviral drugsView all posts for the topic: antiviral drugs
Remdesivir tied to 25% lower risk of in-hospital death in adults with COVID and no added oxygen
Published April 17, 2024
Still COVIDing Canada Posts
Published by: CIDRAP
Published on:
By Mary Van Beusekom
The antiviral drug remdesivir cut death rates 17% to 25% in adults hospitalized for COVID-19 who didn’t require supplemental oxygen at admission, suggests a large US study published yesterday in Open Forum Infectious Diseases.
The study, led by researchers from remdesivir (Veklury) developer Gilead Sciences, used a multicenter US hospital billing database to compare rates of in-hospital death among 58,188 patients on room air who received at least one dose of remdesivir within the first 2 days of hospital admission and 17,574 matched patients not given the drug. The drug is most effective when given early in infection, when viral replication is most active.
Comments closedTopic: long COVIDView all posts for the topic: long COVID
Lessons in persistence
Published April 11, 2024
Still COVIDing Canada Posts
Published by: Science
Published on:
By Jennifer Couzin-Frankel
New Long Covid trials aim to clear lingering virus—and help patients in dire need.
Comments closedTopic: PaxlovidView all posts for the topic: Paxlovid
Paxlovid to no longer be provided to provinces for free
Published April 1, 2024
Still COVIDing Canada Posts
Published by: CTV News
Published on:
By Charles Lefebvre
The Public Health Agency of Canada (PHAC) is no longer paying for an antiviral pill used to treat COVID-19.
The PHAC said it will no longer procure Paxlovid, which is intended to be used after being diagnosed with COVID, for provinces and territories.
“The provinces and territories are responsible for determining how best to implement and manage the available supply of COVID-19 therapeutics, including Paxlovid,” a spokesperson for Health Canada said in a statement.
Comments closedTopic: PaxlovidView all posts for the topic: Paxlovid
13 Things To Know About Paxlovid, the Latest COVID-19 Pill
Published March 25, 2024
Still COVIDing Canada Posts
Published by: Yale Medicine
Published on:
By Kathy Katella
Note: Information in this article was accurate at the time of original publication. Because information about COVID-19 changes rapidly, we encourage you to visit the websites of the Centers for Disease Control & Prevention (CDC), World Health Organization (WHO), and your state and local government for the latest information.
Paxlovid, an oral antiviral pill that can be taken at home, is the go-to treatment for COVID-19. If you are at high risk for severe disease from COVID, and you take it within the first five days of experiencing symptoms, it will lower your risk of getting so sick that you need to be hospitalized.
Comments closedTopic: PaxlovidView all posts for the topic: Paxlovid
Paxlovid use tied to 84% lower risk of hospital care
Published February 21, 2024
Still COVIDing Canada Posts
Published by: CIDRAP
Published on:
By Stephanie Soucheray
University of North Carolina–Chapel Hill investigators report today that COVID-19 hospitalization risk was reduced by 84% among Paxlovid (nirmatrelvir and ritonavir) recipients in a large, diverse healthcare system during January to August 2022, when the Omicron strain was dominant.
The study appears in the Journal of Antimicrobial Chemotherapy. Paxlovid is authorized for use in US patients 12 years and older at risk for developing severe outcomes from COVID-19 infections. In early clinical trials, the use of the antiviral drug was associated with a relative risk reduction of 89% of disease progression to severe illness.
Comments closedTopic: antiviral drugsView all posts for the topic: antiviral drugs
Early Paxlovid for COVID-19 halved death, hospitalization in new study
Published December 19, 2023
Still COVIDing Canada Posts
Published by: CIDRAP
Published on:
By Mary Van Beusekom
Starting the antiviral drug nirmatrelvir-ritonavir (Paxlovid) 0 or 1 day after COVID-19 symptom onset halved 28-day all-cause death and hospitalization rates compared with waiting 2 or more days, University of Hong Kong researchers report in Nature Communications.
Comments closedTopic: PaxlovidView all posts for the topic: Paxlovid
This drug was hailed as a COVID game-changer. Here’s what we know about Paxlovid today
Published November 8, 2023
Still COVIDing Canada Posts
Published by: Toronto Star
Published on:
By Dr. Lynora Saxinger
The drug could help people at high risk, writes Dr. Lynora Saxinger. But COVID has changed. Here’s what you should know about the current risks and benefits.
Comments closedTopic: antiviral drugsView all posts for the topic: antiviral drugs
Pfizer more than doubles price of lifesaving Covid-19 medication Paxlovid as US transitions out of pandemic phase
The price of the lifesaving Covid-19 antiviral medication Paxlovid will more than double as the United States transitions out of the emergency phase of the pandemic, drugmaker Pfizer said Wednesday.
Comments closedTopic: researchView all posts for the topic: research
Smell loss from COVID fades quickly with help of new pill
Published October 17, 2023
Still COVIDing Canada Posts
Published by: Nature
Published on:
By Mariana Lenharo
New clinical-trial data suggest that an antiviral pill called ensitrelvir shortens the duration of two unpleasant symptoms of COVID-19: loss of smell and taste. The medication is among the first to alleviate these effects and, unlike other COVID-19 treatments, is not reserved only for people at high risk of severe illness.
Comments closed